Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts
17 Fevereiro 2009 - 11:56AM
PR Newswire (US)
PRINCETON, N.J., Feb. 17 /PRNewswire-FirstCall/ -- Novo Nordisk, a
global healthcare company focusing on diabetes care, today
announced the appointment of Andy Ajello as vice president for
National Diabetes Sales, Managed Care and Government Accounts.
Ajello joins the Executive Team and will report directly to Jerzy
Gruhn, president of Novo Nordisk's North American affiliate. Ajello
was most recently the associate vice president of Diabetes Sales
for the eastern area, where he led more than 600. In his new
position, he will lead the company's 2,000-person field sales
organization. Ajello joined Novo Nordisk in 2001 where he helped to
launch NovoLog(R) (insulin aspart [rDNA origin] injection). "In his
eight years at Novo Nordisk, Andy has developed an impressive track
record for building high performing field sales teams," said Jerzy
Gruhn, president of Novo Nordisk Inc. "His focus on
cross-functional collaboration, quick decision-making and strategic
execution will help us continue our growth and ultimately realize
our ambition of changing diabetes." Ajello has been recognized and
awarded at Novo Nordisk for achievements in sales leadership,
training, and marketing, including being named as the Novo Nordisk
International Sales Manager of the Year in 2007. Ajello's unique
style and insights into team development and management were
featured in a Wall Street Journal article in 2008. Prior to Novo
Nordisk, Ajello held a 10-year tenure at GlaxoSmithKline. Ajello
received a Bachelor's degree in economics from Susquehanna
University. About Novo Nordisk Novo Nordisk is a healthcare company
with an 86-year history of innovation and achievement in diabetes
care. The company has the broadest diabetes product portfolio in
the industry, including the most advanced products within the area
of insulin delivery systems. In addition to diabetes care, Novo
Nordisk has a leading position within areas such as hemostasis
management, growth hormone therapy, and hormone therapy for women.
Novo Nordisk's business is driven by the Triple Bottom Line: a
commitment to social responsibility to employees and customers,
environmental soundness and economic success. With headquarters in
Denmark, Novo Nordisk employs more than 27,000 employees in 81
countries, and markets its products in 179 countries. Novo
Nordisk's B shares are listed on the stock exchanges in Copenhagen
and London. Its ADRs are listed on the New York Stock Exchange
under the symbol 'NVO'. For global information, visit
novonordisk.com; for United States information, visit
novonordisk-us.com.
http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO
http://photoarchive.ap.org/ DATASOURCE: Novo Nordisk CONTACT:
Media, Sean Clements, +1-609-514-8400, , or Investors, Hans Rommer,
+45-444-24765, , both of Novo Nordisk Web Site:
http://www.novonordisk.com/
Copyright